Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease | Zendy

Kaj Blennow | Zendy; Henrik Zetterberg | Zendy; Juha O. Rinne | Zendy; Stephen Salloway | Zendy; Jenny Wei | Zendy; Ronald S. Black | Zendy; Michael Grundman | Zendy; Enchi Liu | Zendy

Open Access

Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease

Author(s) -

Kaj Blennow,

Henrik Zetterberg,

Juha O. Rinne,

Stephen Salloway,

Jenny Wei,

Ronald S. Black,

Michael Grundman,

Enchi Liu

Publication year - 2012

Publication title -

archives of neurology

Language(s) - English

Resource type - Journals

eISSN - 1538-3687

pISSN - 0003-9942

DOI - 10.1001/archneurol.2012.90

Subject(s) - medicine , placebo , biomarker , cerebrospinal fluid , clinical trial , disease , alzheimer's disease , oncology , gastroenterology , pathology , biology , biochemistry , alternative medicine

Given the slow and variable clinical course of Alzheimer disease, very large and extended clinical trials are needed to identify a beneficial clinical effect of disease-modifying treatments. Therefore, biomarkers are essential to prove that an anti-β-amyloid (Aβ) drug candidate affects both Aβ metabolism and plaque load as well as downstream pathogenic mechanisms.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research